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Triple punch against trypanosomes
Fat cooperation keeps sleeping sickness at bay, say Molina-Portela et al. (page 1721). The authors 
find that all three components of a human high density cholesterol complex are needed to kill 
disease-causing trypanosomes.
Trypanosomes cannot synthesize their own fats, so they feed on the host’s portion, which in 
humans and some other primates includes a cholesterol complex known as the trypanosome lytic 
factor (TLF). Because TLF is toxic to parasites that lack a specific resistance gene, it acts as a 
Trojan horse that kills the bug from within. Of the three lipoproteins in TLF, only apolipoprotein 
(apoL)-1 has been credited for TLF’s killing power, via its ability to drill pores into the parasite’s 
membrane that cause the invader to swell and burst.
The group’s initial results supported the single-fat toxicity idea; mice engineered to produce 
only the apoL-1 component of TLF survived otherwise lethal infections. But when plasma from 
these mice was transferred into normal infected mice, the recipients did not completely clear the 
parasite; animals that were infused with plasma containing all three TLF components did.
Mouse plasma that contained only apoL-1 had 10% of the lytic activity of whole human plasma. 
The authors speculate that this feeble but detectable killing capacity might be due to apoL-1’s 
association with endogenous mouse lipoproteins that are similar to other TLF elements.
The other two TLF components might enhance killing by increasing the uptake of apoL-1 by the 
parasite. One is thought to be a ligand for the parasite’s fat-binding receptor, and the other might direct 
the delivery of the complex to the lysosome, whose acidic environment helps activate apoL-1.
Some trypanosome varieties have a resistance protein that hook to apoL-1’s C terminus, which 
has led to the idea that a version of apoL-1 lacking this domain might provide broad resistance to 
the parasites. But the authors now dismiss this idea, as mice that expressed the truncated lipid were 
still susceptible.
HIV switches to escape
On page 1789, Streeck et al. reveal that a second HIV strain is encouraged by the host’s immune 
pressures to recombine with an earlier strain. Thus thwarted, the immune system fails to keep the 
new strain in check.
Most HIV-infected individuals initially develop a strong CD8+ T cell response against multiple 
epitopes, including those found within HIV’s Gag and Env proteins, some of which eventually develop 
escape mutations. In one HIV-infected individual, the authors found, new CD8+ T cells quickly 
developed against such mutated epitopes while the original T cells waned. Viral levels remained low 
in the patient, suggesting that the variant-specific T cells controlled the mutant HIV strain.
But this control was broken by an apparent second infection in the individual. Soon after it 
entered the host, the second strain recombined with the first. In the resulting strain, the authors 
found switched sequences at the immune-targeted Gag and Env sites. The switch provided the new 
strain with the original version of the first, before the escape mutations occurred. This allowed viral 
levels to reach an all-time high by facilitating viral escape from the CD8+ T cell responses that were 
dominant prior to the second infection. The second strain might distinguish between available 
strains and choose the right one for recombination. More likely, however, viruses lucky enough to 
acquire the right bits of Gag or Env might simply be spared by the weakened T cell response.
CD8+ T cells were eventually regenerated against the switched epitopes, and viral levels decreased. 
But this control was also short lived; a second recombination event at the same regions—this time 
with the mutated version of the first strain—raised viral levels. The findings suggest that, like escape 
mutations, recombination is a trick that HIV uses to stay a step ahead of the immune system.
Ingestion of the entire TLF complex 
causes trypanosomes to swell 
and burst.
Different HIV strains in one 
individual that recombine (red/blue 
overlap) at immune-targeted sites 
escape T cell attack.
Selective signaling
Two receptors that trigger platelet activation relay their signals via different residues on the same 
adaptor, according to Bezman et al. (page 1775).
In platelets, the SLP76 adaptor scaffolds a signaling complex that activates platelets via two 
receptors: the GPVI immunoreceptor and the αIIbβ3 integrin. Three tyrosines at the SLP76 
amino end—Y145, Y112, and Y128—constitute a major part of the molecule’s business end. 